TELIX Pharmaceuticals Ltd (TLX) - Cash Flow Conversion Efficiency

Latest as of June 2025: 0.066x

Based on the latest financial reports, TELIX Pharmaceuticals Ltd (TLX) has a cash flow conversion efficiency ratio of 0.066x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$27.98 Million ≈ $19.80 Million USD) by net assets (AU$421.94 Million ≈ $298.55 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of TELIX Pharmaceuticals Ltd to measure how much of total assets are equity-financed.

TELIX Pharmaceuticals Ltd - Cash Flow Conversion Efficiency Trend (2017–2024)

This chart illustrates how TELIX Pharmaceuticals Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check TLX operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.

TELIX Pharmaceuticals Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of TELIX Pharmaceuticals Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Bains Mer Monaco PA:BAIN	0.082x
SOLV Energy, Inc. Class A Common Stock NASDAQ:MWH	0.459x
Guangzhou Development Group Inc SHG:600098	0.075x
Jiangsu Nhwa Pharmaceutical Co Ltd SHE:002262	0.051x
Xi an Bright Laser Tech Co Ltd SHG:688333	0.022x
Regis Resources Ltd AU:RRL	0.293x
Guangdong Zhongsheng Pharmaceutical Co Ltd SHE:002317	0.021x
NCR Atleos Corporation NASDAQ:NATL	-0.023x

Annual Cash Flow Conversion Efficiency for TELIX Pharmaceuticals Ltd (2017–2024)

The table below shows the annual cash flow conversion efficiency of TELIX Pharmaceuticals Ltd from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see TELIX Pharmaceuticals Ltd stock valuation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	AU$568.21 Million ≈ $402.05 Million	AU$43.03 Million ≈ $30.45 Million	0.076x	-52.79%
2023-12-31	AU$148.91 Million ≈ $105.36 Million	AU$23.88 Million ≈ $16.90 Million	0.160x	+119.29%
2022-12-31	AU$76.92 Million ≈ $54.42 Million	AU$-63.97 Million ≈ $-45.26 Million	-0.832x	+94.89%
2021-12-31	AU$3.64 Million ≈ $2.58 Million	AU$-59.33 Million ≈ $-41.98 Million	-16.290x	-65771.77%
2020-12-31	AU$79.02 Million ≈ $55.91 Million	AU$1.96 Million ≈ $1.39 Million	0.025x	+107.52%
2019-12-31	AU$70.73 Million ≈ $50.05 Million	AU$-23.33 Million ≈ $-16.51 Million	-0.330x	+15.88%
2018-12-31	AU$52.90 Million ≈ $37.43 Million	AU$-20.75 Million ≈ $-14.68 Million	-0.392x	-220.50%
2017-12-31	AU$49.29 Million ≈ $34.88 Million	AU$-6.03 Million ≈ $-4.27 Million	-0.122x	--

About TELIX Pharmaceuticals Ltd

AU:TLX Australia Biotechnology

Market Cap

$3.37 Billion

AU$4.76 Billion AUD

Market Cap Rank

#4602 Global

#112 in Australia

Share Price

AU$14.21

Change (1 day)

+1.00%

52-Week Range

AU$8.63 - AU$20.24

All Time High

AU$31.14